It's a fundamental play not a chart play. They went through a successful Phase III review of the wet macular degeneration eye treatment this summer and have an excellent and safe treatment. They are gearing up for commercial launch next year. It's expected they will have to partner up, get bought out or potentially dilute with shares depending on their long term strategy to go it alone or not since their cash on hand is low. It's meandering but still offers pops that are very lucrative. The big payoff is long term but there are short term pops that matter.
News 
Market Data 
Discover 
